Clinical data | |
---|---|
Other names | E2D; Estradiol decylate; Estradiol 17β-decanoate; Estra-1,3,5(10)-triene-3,17β-diol 17β-decanoate |
Routes of administration | By mouth |
Drug class | Estrogen; Estrogen ester |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H42O3 |
Molar mass | 426.641 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Estradiol decanoate (E2D), or estradiol decylate, also known as estradiol 17β-decanoate, is a synthetic steroidal estrogen and an estrogen ester – specifically, the 17β-decanoate (decylate) ester of estradiol – which was studied for use in hormone replacement therapy for ovariectomized women in the late 1970s but was never marketed.
Oral estradiol decanoate in oil at a dosage of 0.25 to 0.5 mg/day for 14 days has been studied in ovariectomized women and found to produce levels of estrone and estradiol with a ratio of about 1:2 (0.5) to 1:1.7 (0.6). This is in contrast to oral micronized estradiol, which has an estrone to estradiol ratio of about 5:1 (an 8- to 10-fold difference in ratio relative to oral estradiol decanoate in oil). The normal ratio of estrone to estradiol in women is about 1:2 (0.5) in premenopausal women and about 2:1 in postmenopausal women. As such, oral estradiol decanoate in oil may provide a more physiological and favorable profile of estrone and estradiol levels than oral micronized estradiol.
The improved estrone to estradiol ratio of oral estradiol decanoate in oil is likely related to absorption via the intestinal lymphatic system, which allows for bypassing of first-pass metabolism in the liver. This is dependent on the fatty acid decanoate ester of estradiol decanoate, and in accordance, oral estradiol decanoate not dissolved in oil has less or absent effects in rodents. Absorption of oral estradiol decanoate in oil via the lymphatic system is analogous to the case of oral testosterone undecanoate in oil.
See also
References
- ^ Kicovic PM, Luisi M, Franchi F, Alicicco E (July 1977). "Effects of orally administered oestradiol decanoate on plasma oestradiol, oestrone and gonadotrophin levels, vaginal cytology, cervical mucus and endometrium in ovariectomized women". Clin. Endocrinol. (Oxf). 7 (1): 73–7. doi:10.1111/j.1365-2265.1977.tb02941.x. PMID 880735. S2CID 13639429.
- ^ Luisi M, Kicovic PM, Alicicco E, Franchi F (1978). "Effects of estradiol decanoate in ovariectomized women". J. Endocrinol. Invest. 1 (2): 101–6. doi:10.1007/BF03350355. PMID 755846. S2CID 38187367.
- Ranjit Roy Chaudhury (1 January 1981). Pharmacology of Estrogens. Elsevier Science & Technology Books. p. 36. ISBN 978-0-08-026869-9.
- ^ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
- ^ de Visser J, van der Vies J (June 1977). "Oestrogenic activity of oestradiol-decanoate after oral administration to rodents". Acta Endocrinol. 85 (2): 422–8. doi:10.1530/acta.0.0850422. PMID 577331.
- Alexandre Hohl (30 March 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 207–. ISBN 978-3-319-46086-4.
This article about a steroid is a stub. You can help Misplaced Pages by expanding it. |
This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it. |